|
Synonyms: ch38SB19 | hu38SB19 | isatuximab-irfc | SAR-650984 | SAR650984 | Sarclisa®
isatuximab is an approved drug (EMA & FDA (2020))
Compound class:
Antibody
Comment: Isatuximab is an anti-CD38 monoclonal antibody that was designed for anti-tumour potential [2].
A patent search identifies the peptide sequences of the light and heavy chain variable regions of isatuximab as SEQ ID NO: 22 and SEQ ID NO: 21 from patent US 8877899 B2 [6] (and equates to Ref mAB5 in the patent document). This patent further refers these sequences to WO2008047242 A8, but neither this or any associated patent (eg US20110262454 A1) provide peptide sequences to allow identification of isatuximab therein. The most likely patent defined embodiment being isatuximab is hu38SB19 [4]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Isatuximab has completed Phase 1-3 clinical trials for its potential to treat hematological malignancies [1-2,5]. It was granted FDA approval in early March 2020 [3] and EMA authorisation in May 2020. These approvals authorise isatuximab's use in combination with pomalidomide and dexamethasone in a defined set of patients with relapsed refractory multiple myeloma. Eligible patients must have received at least two prior therapies including lenalidomide and a protease inhibitor. |
| Mechanism Of Action and Pharmacodynamic Effects |
| CD38+ cells are present in diverse hematologic malignancies, including multiple myeloma, B-cell non-Hodgkin lymphoma (NHL), B-cell chronic lymphocytic leukemia, B-cell acute lymphoblastic leukemia (ALL), and T-cell ALL. CD38 is a validated molecular target for antineoplastic drug development for these indications. In preclinical experiments, anti-CD38 antibody isatuximab exhibits strong proapoptotic activity and potent effector functions (complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP)) [2]. |
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |
